Drug-induced QT prolongation is the leading cause of FDA nonapproval and a key safety concern for many medications, including cardiac drugs, antibiotics, psychotropic drugs, and oncology treatments. Conventional automated QT algorithms have shown variable reliability in recordings with abnormal or irregular morphology, with misclassification rates up to 75%. This article presents SafeBeat Rx, an AI-powered ECG platform that provides beat-by-beat ECG analysis, enabling full transparency and optional adjustment of measurements for each individual ECG heartbeat. Validated against expert cardiologist adjudication, SafeBeat addresses a critical gap in postdischarge cardiac surveillance and represents a novel approach to guideline-adherent pharmacological disease management.